A Phase Ia/Ib, Open-Label, Multi-center, First in Human and Expansion Study to Assess the Safety, Tolerance, and Pharmacokinetics of the Novel Antitumor Agent CBP-1008 in Patients With Advanced Solid Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs CBP-1008 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Coherent Biopharma (Suzhou)
- 04 Jun 2024 Results assessing safety and efficacy of CBP-1008, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (n=178; As of September 30, 2022) assessing the safety and efficacy of CBP-1008 in patients with advanced solid tumors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 27 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Mar 2024.